High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

Background VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective immunotherapy treatment capable of durable remission in some patients but its un...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	S. Chow, V. Galvis, M. Pillai, R. Leach, E. Keene, A. Spencer-Shaw, A. Shablak, J. Shanks, T. Liptrot, F. Thistlethwaite, R. E. Hawkins
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2016-11-01
Online Access:	https://jitc.bmj.com/content/4/1/67.full